// App-Quantinova.ai

1697 : Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the BELIEVE Trial

Researchers

Presenter

  • Olivier Hermine

Principal Investigators

  • Ali T. Taher

  • Thomas D. Coates

  • Vip Viprakasit

  • Ersi Voskaridou

  • Ashutosh Lal

  • Hong Keng Liew

  • Silverio Perrotta

  • Abderrahim Khelif

  • Antonis Kattamis

  • Jeevan K. Shetty

  • George Zhang

  • Yu (Olivia) Tian

  • Dimana Miteva

  • Tatiana Zinger

  • Derek Tang

  • Jay T. Backstrom

  • John B. Porter

Medical Centers

  • Imagine Institute, INSERM U1163, University of Paris, Paris, France

  • Department of Haematology, Tenon University Hospital, Assistance Publique Hopitaux de Paris, Paris, France

  • Fondazione IRCCS Ca' Granda Maggiore Hospital, University of Milan, Milan, Italy

  • Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA

  • UCLA School of Medicine, Los Angeles, CA

  • Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • Thalassemia and Sickle Cell Disease Center, Laikon University General Hospital, Athens, Greece

  • University of California San Francisco Benioff Children's Hospital,Oakland,United States

  • Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

  • Universita Della Campania "Luigi Vanvitelli", Napoli, Italy

  • Farhat Hached Teaching Hospital, Sousse University,Sousse,Tunisie

  • First Department of Radiology, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Acceleron Pharma, Cambridge, MA

  • University College London and University College London Hospitals NHS Foundation Trust, London, United Kingdom

Locations

  • France

  • Italy

  • Lebanon

  • United States

  • Thailand

  • Greece

  • Malaysia

  • Tunisia

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemochromatosis

  • Thalassemia

Biomarkers

  • Red Blood Cells

Drug/Treatment

  • Deferoxamine

  • luspatercept

  • Deferasirox

  • Deferiprone

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

Phase

  • III

Study Id's

  • NCT02604433

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved